NCT02431468: A trial that was reported late by Neurotrope Bioscience, Inc.
This trial has reported, although it was 61 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02431468 |
|---|---|
| Title | A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 30, 2015 |
| Completion date | Feb. 28, 2017 |
| Required reporting date | Feb. 28, 2018, midnight |
| Actual reporting date | April 30, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 61 |